EXHIBIT 99.1
JOINT FILING AGREEMENT
The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the ordinary shares of Adaptimmune Therapeutics, a public limited company incorporated under the laws of England and Wales, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.
This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
Dated this 9th day of May, 2022.
| PFM Health Sciences, LP | PFM Health Sciences GP, LLC | |||
| By: | PFM Health Sciences GP, LLC, | By: | /s/ Darin Sadow | |
| its general partner | Darin Sadow, Authorized Signatory | |||
| By: | /s/ Darin Sadow | |||
| Darin Sadow, Authorized Signatory | ||||
| PARTNER Asset MANAGEMENT, LLC | BRIAN D. GROSSMAN | |||
| By: | PFM Health Sciences GP, LLC, | By: | /s/ Darin Sadow | |
| its manager | Darin Sadow, attorney-in-fact | |||
| By: | /s/ Darin Sadow | |||
| Darin Sadow, Authorized Signatory | ||||